Member Info for Jarv55

https://twitter.com/rick_shares/status/1145600228453732352
Lovely

Massive news today looking forward to the re-rate here

Worth a read as to their plans this year
https://s3.eu-west-2.amazonaws.com/document-api-images-live.ch.gov.uk/docs/EIIDN-DaPjbSxuOaJN7ndU_oU8bbAyhUaPkB0eWqSis/application-pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAWRGBDBV3G3466CSS%2F20190630%2Feu-west-2%2Fs3%2Faws4_request&X-Amz-Date=20190630T080417Z&X-Amz-Expires=60&X-Amz-Security-Token=AgoJb3JpZ2luX2VjED8aCWV1LXdlc3QtMiJGMEQCIDmdeZf1WM5JusWvskFLaBlz8llDByx5a8eLbd8tWTt2AiAYDi0GkGLvndhdhTmBmH7zsINOBuCWdANsSZiu3BMlUirjAwiI%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAEaDDQ0OTIyOTAzMjgyMiIMMhq96D%2Fl2Cmqt8iHKrcDecLvMarcK%2BkKDjGgVbJ4MAH%2FgRAz2KayLdULZdPGci9f5c%2FSbXCp%2FJuGDkGTdonLy51w2o1WOIepBqeVCKTRxb57t7kTch8Wur2Piy8tNAq4w7MYBKAJN1QT9Bgch11ZL0QYnIUkChE4B1KzxOwtWrPbU7HGqD3EV97D5taELAx51CmHLLTGplVPiMuKm%2Bov7oxnU%2FlO1rgvrHXGhegQr9BmQ49cfCBXFglzyjnsbR98NP4%2B5JMBPFrV%2FL4t7jIFOMQlRrzPj50RIRTu8botSJvQLEOfy9Tin5Vla41%2BMNbUS8QypiKYv45%2FTRfbS8jMFi3dTIZx6BHg8aviMQr1TgwvvJmGharQBWcP2evpx3jD0InJjoA6sUzwuhB39jS5Osk%2BZdAGFU2ukX1Oo%2BoqORkrKgZP7tRAK%2F9iH7qRgg3GJaOi%2BW20UB8IMtBYW51zVOFcUxVBnVTS85kWm%2BZieyas7psZVrt%2Fmc%2BPfQSRTqwqaq2IlVfpNrvRHjyJdRG50zVl%2FySfkNTqjFbathcn%2FpcyIGLvlxyzhyJua2nhrZ7ffEQrYST%2BlxgjrJAP7vPw%2B23RnoUs%2FjC6t%2BHoBTq1ASj6Ai7RUKU9D2NJO2vtcH5QHkS9uORSMzrmQeDckfFXAU434eM63XIICxXbnbkbkvTiH2QW%2FiO%2Byc5vA4o%2F0U%2BT5OI6BR3jrH%2FjiTXTmu0xp5b%2FyMl4myLkQZSuhjf2Rv1%2FdJ0iCR725Xjww32rBnyaQm8RXFk2JtXHathB90jkf%2FAFQ2EcbHs2VSIz%2FMPXNN1occn03peviCi8ji4SlnIfxOfIse%2FRykBmvfDee9tKvE8BlQU%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=5e7107ff86fca164b943dbbc00666657958523d8d962607069cf081b669ce42d

e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, and Novo Nordisk.

then look at the Green disc you will see the relevance

Cash open the link

According to the new report, investment in AI for Drug Discovery startups increased from $200 million in 2015 to over $700 million in 2018 DKA

As the research indicates, the declining R&D efficiency of Biopharma companies remains a primary concern among all parties in the industry with a continuous decline recorded during the last eight years. The antibiotics industry is closely affected by this decline and it causes severe concerns about the future. The number of new antibiotics approved by the US Food and Drug Administration (FDA) has declined between 1983 and 2012, according to an OECD report on how to tackle antimicrobial resistance. Also, according to 2016 data, there are fewer big pharma companies with an active antibiotic R&D pipeline. There are only six such companies, whereas in 1990 there were 18. New antibiotics are becoming increasingly challenging to discover and typically only 1.5 percent of antibiotics in preclinical development finally reach the market.

AI technologies could offer solutions to the problem allowing for faster drug development and by cutting down on the cost of preclinical research. The emerging field of precision medicine raises hopes to companies and patients that the future will give more opportunities to overcome the obstacles posed by lack of resources or expertise.

Have a read interesting posted by Rick on twitter https://www.forbes.com/sites/yiannismouratidis/2019/05/05/old-evaluation-systems-are-inadequate-for-ai-health-care-and-drug-development-ecosystem/amp/?__twitter_impression=true

late trades last of Woodford?

If it stays like this I won't be using it it is messing with my eyes.

It is awful

Could have the rns after hours know someone who rang Numis he only has 0.1% left

Look at the monthly chart plenty of value in this https://invst.ly/b4msi

Would't be surprised if its another insti loading up

Think we are going to see a nice move North this afternoon plenty of buyers picking these up now.

Oh dear Ronald is getting burnt

Coffeecups his posts are hilarious I don't think he is going to get his pay check though roll on the TR1 to say Woodford is out could come anytime today.

Gazzacog rehashed article https://clinicaltrials.gov/ct2/show/NCT01489826?term=Dexanabinol&rank=3

Ronald Mcdonald going to have to report you for misleading de-ramping information.

R&D spend for the year of £3.7m (2018: £5.0m) was £1.3m lower than the prior year. The last remaining clinical trial, ETS2101, ended in August 2018 and this, combined with reduced spend on the self-funded assets, accounted for the majority of the reduction in R&D spend.

Administrative costs in the year of £1.5m (2018: £1.7m) continue to decline, primarily due to a reduction in people costs.

Year end cash and cash equivalents were £5.9m (2018: £9.6m). The cash reduction for the year as a whole was £3.7m (2018: £4.4m). After adjusting for the R&D tax credit of £1.4m (2018: £3.0m) the underlying cash burn of £5.1m was in line with the operating loss. This compares with an underlying cash burn in the prior year of £7.4m.

In the second half of the year, the cash reduction of £1.7m was the lowest half yearly burn rate since 2011. It is important to be aware that whilst we are continually looking at all costs, we have continued and will continue to invest in both core NDD platform functionality and the self-funded assets. The decision to increase investment in the platform was made over two years ago and this is evidenced by the advances we have made over the last 12 months in patient-specific segmentation, our proprietary database expansion and the recent C4X Discovery collaboration.

Notwithstanding the fact that we will continue to invest within both the platform and the self-funded assets, we anticipate a further, more modest, reduction in operating loss in the current year.

We are anticipating claiming an R&D tax credit of £1.1m for the current financial year. Combined with our year end cash position and based on the second half cash consumption exit rate, we maintain our expectation that we will have sufficient cash to continue core operations into late 2020. However, as always, this will need to be evaluated if we wish to invest in further experimental validation of new NDD-derived programmes or later stage preclinical work.

Someone is buying in 100k chunks